We acquire future potential milestone and royalty rights associated with pre-commercial therapeutic assets that are being developed by global pharmaceutical and biotech companies.
We understand the value of milestone and royalty rights. For biotech companies, monetizing these assets results in an infusion of non-dilutive, non-recourse capital to fund operations and pursue clinical goals.
If you or your company have a royalty license for a pre-commercial therapeutic that is in active development with a partner, we are happy to talk with you about how XOMA may be able to provide you with non-dilutive, non-recourse capital.